IVIEW Therapeutics
Cranbury, US · Delaware corporation · 3 known investors
Founders & leadership
BL
Bo LiangFounder
HH
Houman HemmatiExecutive
WW
Wei WangNamed on SEC filing
JJ
John J BaldwinNamed on SEC filing
TD
Tao DuNamed on SEC filing
Board
QZ
Qi ZhuBoard director
JL
Jingjie LiBoard director
XS
Xiaolu SunBoard director
BH
Bin HeBoard director
Investors · 3
Also in the syndicate · 2
Chongqing Changsheng Shenghe InvestmentProxima venture
Reported raises · per SEC filings
Form D private placements$39.2M disclosed across 2 rounds · 2021–2024
▶$9.2MraisedJun 2025 · 5 investors · BiotechnologyRule 506(b)
▶$9.2MraisedJun 2025 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Qi ZhuDirector
- Houman HemmatiExecutive Officer, Director
- Wei WangExecutive Officer, Director
- Jingjie LiDirector
- Xiaolu SunDirector
- Bo LiangExecutive Officer, Director
- Bin HeDirector
- Offering amount
- $15M
- Amount sold
- $9.2M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30MraisedJan 2022 · 15 investors · PharmaceuticalsRule 506(b)
▶$30MraisedJan 2022 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John J BaldwinDirector
- Wei WangExecutive Officer, Director
- Bo LiangExecutive Officer, Director
- Qi ZhuExecutive Officer, Director
- Xiaolu SunDirector
- Bin HeDirector
- Tao DuDirector
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapOis13 shared keywordsOIS is a conference and community, active since 2009, focused on eye care and ophthalmology innovation, connecting startups, strategics, investors, and clinicians. It provides curated programming, networking, and access to new technologies in the ophthalmology industry.
Bioworld9 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Eyconis7 shared keywordsEyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform. The company aims to reduce treatment burden for patients by extending the duration between required injections while improving disease control and visual outcomes.
Companies competing with IVIEW Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $579.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $323.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- Who founded IVIEW Therapeutics?
- IVIEW Therapeutics was founded by Bo Liang.
- Who are IVIEW Therapeutics's investors?
- IVIEW Therapeutics's investors include BioAdvance.
- How much funding has IVIEW Therapeutics raised?
- IVIEW Therapeutics has disclosed $39.2M raised across 2 rounds.
- Where is IVIEW Therapeutics headquartered?
- IVIEW Therapeutics is headquartered in Cranbury, US.